High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial.

Channing J Paller Marianna L Zahurak Adel Mandl Nicole A Metri Aliya Lalji Elisabeth I Heath William Kevin Kelly Christopher J Hoimes Pedro C Barata Jason Taksey Dominique A Garrison Kartick Patra Ginger L Milne Nicole M Anders Julie M Nauroth Jennifer N Durham Catherine Handy Marshall Mark C Markowski Mario A Eisenberger Emmanuel S Antonarakis Michael A Carducci Samuel R Denmeade Mark Levine

Published in: Cancer research communications (2024)

This is the first randomized, placebo-controlled, double-blind trial to evaluate HDIVC in cancer treatment. The addition of HDIVC to docetaxel in patients with mCRPC does not improve PSA response, toxicity, or other clinical outcomes compared with docetaxel alone. The routine use of HDIVC in mCRPC treatment is not supported outside of clinical trials.

Keyphrases

placebo controlled
double blind
clinical trial
phase iii
phase ii
high dose
study protocol
locally advanced
prostate cancer
phase ii study
squamous cell carcinoma
open label
low dose
small cell lung cancer
stem cell transplantation
randomized controlled trial
oxidative stress
radical prostatectomy